ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 000777

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

Identifieur interne : 000777 ( PascalFrancis/Curation ); précédent : 000776; suivant : 000778

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

Auteurs : Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0387232

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Akinésie, Parkinson maladie, Dose unique, Voie intraveineuse, Piribédil, Homme, Pharmacocinétique, Etude double insu, Pharmacodynamie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Akinesia, Double blind study, Human, Intravenous administration, Nervous system diseases, Parkinson disease, Pharmacodynamics, Pharmacokinetics, Piribedil, Single dose.

Abstract

This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 20`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study`
A11	`01`	`1`		`@1 SIMON (Nicolas)`
A11	`02`	`1`		`@1 MICALLEF (Joëlle)`
A11	`03`	`1`		`@1 REYNIER (Jean-Charles)`
A11	`04`	`1`		`@1 LESOURD (Monique)`
A11	`05`	`1`		`@1 WITJAS (Tatiana)`
A11	`06`	`1`		`@1 ALICHERIF (André)`
A11	`07`	`1`		`@1 AZULAY (Jean-Philippe)`
A11	`08`	`1`		`@1 BLIN (Olivier)`
A14	`01`			`@1 Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone @2 Marseille @3 FRA @Z 1 aut.`
A14	`02`			`@1 CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée @2 Marseille @3 FRA @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`03`			`@1 Institut de Recherches Internationales Servier @2 Courbevoie @3 FRA @Z 4 aut.`
A20				`@1 803-809`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000132363110040`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 05-0387232`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Akinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Akinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Aquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 03`
C03	`04`	`X`	`FRE`	`@0 Dose unique @5 09`
C03	`04`	`X`	`ENG`	`@0 Single dose @5 09`
C03	`04`	`X`	`SPA`	`@0 Dosis única @5 09`
C03	`05`	`X`	`FRE`	`@0 Voie intraveineuse @5 10`
C03	`05`	`X`	`ENG`	`@0 Intravenous administration @5 10`
C03	`05`	`X`	`SPA`	`@0 Vía intravenosa @5 10`
C03	`06`	`X`	`FRE`	`@0 Piribédil @2 NK @2 FR @5 11`
C03	`06`	`X`	`ENG`	`@0 Piribedil @2 NK @2 FR @5 11`
C03	`06`	`X`	`SPA`	`@0 Piribedil @2 NK @2 FR @5 11`
C03	`07`	`X`	`FRE`	`@0 Homme @5 12`
C03	`07`	`X`	`ENG`	`@0 Human @5 12`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`08`	`X`	`FRE`	`@0 Pharmacocinétique @5 13`
C03	`08`	`X`	`ENG`	`@0 Pharmacokinetics @5 13`
C03	`08`	`X`	`SPA`	`@0 Farmacocinética @5 13`
C03	`09`	`X`	`FRE`	`@0 Etude double insu @5 14`
C03	`09`	`X`	`ENG`	`@0 Double blind study @5 14`
C03	`09`	`X`	`SPA`	`@0 Estudio doble ciego @5 14`
C03	`10`	`X`	`FRE`	`@0 Pharmacodynamie @4 CD @5 96`
C03	`10`	`X`	`ENG`	`@0 Pharmacodynamics @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Trouble moteur @5 39`
C07	`03`	`X`	`ENG`	`@0 Motor system disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Trastorno motor @5 39`
C07	`04`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`04`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`04`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
N21				`@1 269`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C57

Links to Exploration step

Pascal:05-0387232

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study</title>
<author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0387232</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0387232 INIST</idno>
<idno type="RBID">Pascal:05-0387232</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C57</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000777</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study</title>
<author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Akinesia</term>
<term>Double blind study</term>
<term>Human</term>
<term>Intravenous administration</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Pharmacodynamics</term>
<term>Pharmacokinetics</term>
<term>Piribedil</term>
<term>Single dose</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Akinésie</term>
<term>Parkinson maladie</term>
<term>Dose unique</term>
<term>Voie intraveineuse</term>
<term>Piribédil</term>
<term>Homme</term>
<term>Pharmacocinétique</term>
<term>Etude double insu</term>
<term>Pharmacodynamie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SIMON (Nicolas)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MICALLEF (Joëlle)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>REYNIER (Jean-Charles)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LESOURD (Monique)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WITJAS (Tatiana)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ALICHERIF (André)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>AZULAY (Jean-Philippe)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BLIN (Olivier)</s1>
</fA11>
<fA14 i1="01"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>803-809</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000132363110040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0387232</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Akinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Akinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Aquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dose unique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Single dose</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dosis única</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Voie intraveineuse</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Intravenous administration</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vía intravenosa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Piribédil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Piribedil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Piribedil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Pharmacocinétique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Pharmacokinetics</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Farmacocinética</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pharmacodynamie</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pharmacodynamics</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble moteur</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Motor system disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno motor</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fN21><s1>269</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000777 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000777 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0387232
   |texte=   End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri